Openbookopenbook
Openbook
GNOM
+7.32 · +18.32%
$47.24 · NASDAQ

Global X Genomics & Biotechnology ETF (GNOM) ETF Analysis | Health

Global X Funds · USA
AUM:$51.9M
#– of – in Health ETFs

Educational tool only – Figures are based on historical data, holdings and expense metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Market Performance

Up 28.1% over the past year, reflecting strong price momentum.

Cost Efficiency

Ongoing charge of 0.50% — moderate cost. Consider how fees compound over long holding periods.

What is GNOM?

The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, Genomics & Biotechnology Companies), as defined by Solactive AG, the provider of the underlying index.

Performance Highlights

Returns (%)
Top Sectors (%)

Investment Breakdown

Strong Recent Performance
GNOM delivered 28.1% over the past year. Historical returns only — past performance is not indicative of future results.
Moderate Cost
Expense ratio of 0.50%. Consider how fees compound over a long holding period.
Moderate Concentration
Top 10 holdings make up 49.5% of the ETF — a moderate level of name concentration.
ETF Information
AUM$51.9M
Expense Ratio0.50%
Dividend Yield1.31%
Holdings49
Inception DateApr 2019
Domicile–
Distribution–
Index–
ProviderGlobal X Funds
Beta1.93
CategoryHealth
CurrencyUSD
Portfolio Impact

How would GNOM affect your portfolio?

Sign in to see exactly what adding this ETF changes — sector exposure, yield, diversification, volatility. Real numbers from your actual holdings.

Sign in
Example preview
6168
+7 points · better diversified

Chart Tools

My Portfolio

Sign in to overlay your portfolio on the chart.

Sign in
Compare Equity
Uses ISF.L (iShares FTSE 100 ETF)
Indicators

Performance Metrics

Historical returns

6M
+36.0%
1Y
+78.2%
3Y
+46.1%
5Y
-31.7%
OpenBook InsightIf you had invested £10,000 in GNOM 5 years ago, it would have fallen to £6,829 — a loss of £3,171.

Annual Returns

Calendar year performance

GNOM delivered positive returns in 2 of the last 5 calendar years.
YearGNOM
2026 YTD+41.9%
2025+17.5%
2024-16.9%
2023-7.7%
2022-36.7%
CAGR 4yr-13.1%
2/5 positive yearsAvg return: -0.4%Worst year: -36.7% (2022)

Technical Analysis Summary

Automated insights from historical price action and indicators

Technical Regime: POSITIVE
Trend Strength
100%
Positive
Volatility
49.7%
Very High
Momentum
+21.0%
30-day change
Support Level
54.89
Key floor
Key Insights
  • Price is currently trading above all key moving averages.
  • Momentum is upward with a 21.0% move over 30 days.
  • Elevated volatility indicates higher short-term price variability and risk.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.